PMID- 10640962
OWN - NLM
STAT- MEDLINE
DCOM- 20000216
LR  - 20061115
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 88
IP  - 2
DP  - 2000 Jan 15
TI  - Precancerous hepatic nodules had significant levels of telomerase activity 
      determined by sensitive quantitation using a hybridization protection assay.
PG  - 312-7
AB  - BACKGROUND: Telomeric repeat amplification protocol using internal telomerase 
      assay standard (ITAS) (conventional TRAP) has detected telomerase activity in 
      various malignant tumors. With conventional TRAP, it is difficult to 
      differentiate quantitatively low levels of telomerase activity between 
      well-differentiated hepatocellular carcinomas (HCCs) and dysplastic nodules 
      because of quantitative limitation. To apply a telomerase assay for differential 
      diagnosis, we used a hybridization protection assay combined with TRAP 
      (TRAP/HPA). This combination had better sensitivity and wider linearity than 
      conventional TRAP. METHODS: TRAP/HPA was applied for quantitative measurement of 
      telomerase activity in various hepatic tissues. Telomerase activity was evaluated 
      in 10 precancerous hepatic nodules, 17 well-differentiated HCCs, 19 moderately 
      differentiated HCCs, 5 poorly differentiated HCCs, 22 nontumorous chronic hepatic 
      disease samples, and 2 normal liver tissues. RESULTS: Telomerase activity in HCCs 
      tended to increase according to the malignant transformation. The average 
      relative telomerase activity in 0.6 microg protein, which was expressed as cell 
      equivalent activity of MKN-1, a gastric carcinoma cell line, was 8.5 in 
      precancerous hepatic nodules, 87 in well-differentiated HCCs, 265 in moderately 
      differentiated HCCs, 447 in poorly differentiated HCCs, and 0.4 in nontumorous 
      hepatic tissues, including chronic liver diseases. CONCLUSIONS: TRAP/HPA was 
      sensitive enough to distinguish the telomerase activity in precancerous hepatic 
      nodules from that in other lesions. Telomerase activity in precancerous hepatic 
      nodules was higher than that in nontumorous hepatic tissues. However, the 
      activity in precancerous hepatic nodules was lower than that in 
      well-differentiated HCCs, although statistically not significant. The authors 
      suggest that precancerous hepatic nodules with telomerase activity above the 
      diagnostic cutoff level (twice the highest activity in nontumorous hepatic 
      tissues, or the 2 cell equivalent activity of MKN-1) should be treated as 
      malignancy.
CI  - Copyright 2000 American Cancer Society.
FAU - Takaishi, H
AU  - Takaishi H
AD  - First Department of Internal Medicine, Hiroshima School of Medicine, Hiroshima, 
      Japan.
FAU - Kitamoto, M
AU  - Kitamoto M
FAU - Takahashi, S
AU  - Takahashi S
FAU - Aikata, H
AU  - Aikata H
FAU - Kawakami, Y
AU  - Kawakami Y
FAU - Nakanishi, T
AU  - Nakanishi T
FAU - Nakamura, Y
AU  - Nakamura Y
FAU - Shimamoto, F
AU  - Shimamoto F
FAU - Kajiyama, G
AU  - Kajiyama G
FAU - Ide, T
AU  - Ide T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (DNA Primers)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - DNA Primers
MH  - Humans
MH  - Liver/enzymology
MH  - Liver Neoplasms/*enzymology
MH  - *Nucleic Acid Amplification Techniques
MH  - *Nucleic Acid Hybridization
MH  - Precancerous Conditions/*enzymology
MH  - Sensitivity and Specificity
MH  - Telomerase/analysis/*metabolism
EDAT- 2000/01/21 09:00
MHDA- 2000/02/19 09:00
CRDT- 2000/01/21 09:00
PHST- 2000/01/21 09:00 [pubmed]
PHST- 2000/02/19 09:00 [medline]
PHST- 2000/01/21 09:00 [entrez]
AID - 10.1002/(SICI)1097-0142(20000115)88:2<312::AID-CNCR10>3.0.CO;2-R [pii]
PST - ppublish
SO  - Cancer. 2000 Jan 15;88(2):312-7.